Peptide research, regulation, discovery. Every story links to the peptide it’s about.
RSSIn a records study of more than 4,200 patients, adults with type 2 diabetes and peripheral artery disease had about half the major amputations and a quarter fewer deaths on a GLP-1 drug versus metformin. The heart attacks, strokes, and kidney events the class usually moves did not differ.
A Korean national cohort ran the same GLP-1 patients against two comparison drugs and got two answers: no mental-health difference versus DPP-4 inhibitors, a 20 percent higher depression risk versus SGLT2 inhibitors. The comparator, not the drug, is driving the headline.
In 51,540 older adults with type 2 diabetes, tirzepatide was tied to about 35 percent less new open-angle glaucoma over two years than GLP-1-only drugs. The comparison isolates the drugs, not the disease, and the signal still needs a trial to confirm it.
Liver tumors that stop responding to lenvatinib rewire how they burn sugar, turning down the AMPK fuel gauge and ramping up glycolysis. In cells, a GLP-1 receptor agonist reversed that switch and restored the drug's effect, a preclinical mechanism for why GLP-1 drugs keep surfacing in cancer research.
A meta-analysis of retatrutide's randomized trials found a consistent systolic blood-pressure drop near 7 mmHg and falling total cholesterol, LDL, and triglycerides, but no change in HDL and high trial-to-trial disagreement on cholesterol.
A Phase 2b trial in China found a new biweekly GLP-1 drug beat semaglutide 1 mg on HbA1c, but gastrointestinal side effects ran about 30 points higher and the comparator was the lower semaglutide dose.
A pooled analysis of orforglipron, the oral GLP-1 pill, shows a clean dose-response on weight and blood sugar across three trials and 2,505 people. The authors rated several of the key outcomes low certainty.
A Molecular Metabolism study ran obese mice through a five-tastant lick test and found chronic semaglutide left taste sensitivity, taste cells, and taste genes unchanged while still cutting how much they ate. The appetite effect points at motivation, not the tongue.
A Diabetologia study using human donor islets and mouse genetics finds liraglutide's push on insulin runs mostly through a hypothalamic brain gate in healthy bodies, then hands off to a direct pancreatic route as metabolic disease sets in. It is a mechanism for the variability clinicians already see.
A meta-analysis of eight cardiovascular trials and 70,822 patients found GLP-1 drugs cut major heart events by 17 percent whether kidney function was normal or reduced. Because reduced-kidney patients have more events to start with, the same cut prevented more: 39 treated to stop one event versus 62.
A meta-analysis of 11 trials and 25,067 people pooled semaglutide's reduction in major cardiovascular events at 32 percent, and the result held when the obesity and heart-failure trials were removed. The same pooling quantified the costs: more than double the gallbladder events and gut-driven dropouts.
A meta-analysis of seven randomized trials found GLP-1 drugs added about five kilograms of weight loss six months after bariatric surgery, but the benefit was no longer statistically reliable at a year. And every trial tested liraglutide, not the stronger drugs people actually use now.
HRS-7535, a once-daily oral GLP-1 pill, cut body weight up to 9.4 percent over 26 weeks in a 235-person Chinese Phase 2 trial. But the 120 mg dose lost less than the 60 mg dose, and the lowest dose missed placebo entirely.
A Swedish registry of 14,694 people found semaglutide linked to 21 percent fewer psychiatric hospitalizations during the months patients took it. Liraglutide and dulaglutide, which hit the same receptor, showed nothing. The authors say it is not a class effect.
A target trial emulation in All of Us found adults who started semaglutide were about half as likely to develop a new seizure disorder, and the benefit ran through neither glucose control nor weight loss.